Familial partial lipodystrophy type 2 is a rare disease, particularly when it is caused by nonclassical gene variants. A high index of suspicion is essential for a timely diagnosis. We present the case of a 32-year-old woman, referred to evaluation of a possible Cushing syndrome, which was clinically and biochemically ruled out. Yet, due to the finding of a rather abnormal fat distribution during physical examination, the diagnosis of lipodystrophy was cogitated. Whole-exome sequencing revealed a missense variant of exon 11 R582H of the gene encoding Laminin A (rs57830985,c.1745G>A, p.Arg582His). The patient presented some clinical and biochemical characteristics discordant with those previously reported in patients harboring other classical variants of this gene.
case report • Arch. Endocrinol. Metab. 69
(1)
• 2025 • https://doi.org/10.20945/2359-4292-2024-0293 linkcopy
A case of familial partial lipodystrophy type 2 masquerading as Cushing syndrome: Explaining an atypical phenotype by whole-exome sequencing
Authorship
person Enid Perez-Dionisio
reviewed the results · approved the final version of the manuscript · case conception · design · data collection · clinical analysis · interpretation of results
schoolServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Silvia Hinojosa-Alvarez
reviewed the results · approved the final version of the manuscript · execution · interpretation of molecular biology studies
person Rocio Alejandra Chavez-Santoscoy
reviewed the results · approved the final version of the manuscript · execution · interpretation of molecular biology studies
person Regina de Miguel-Ibañez
reviewed the results · approved the final version of the manuscript · case conception · design · data collection · clinical analysis · interpretation of results
schoolServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Manuel Garcia-Saenz
reviewed the results · approved the final version of the manuscript · clinical analysis · interpretation of results
schoolServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Daniel Marrero-Rodriguez
reviewed the results · approved the final version of the manuscript · execution · interpretation of molecular biology studies · draft manuscript preparation
schoolUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Keiko Taniguchi-Ponciano
reviewed the results · approved the final version of the manuscript · execution · interpretation of molecular biology studies
schoolUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Jesus Henandez-Perez
reviewed the results · approved the final version of the manuscript · execution · interpretation of molecular biology studies
person Moises Mercado
reviewed the results · approved the final version of the manuscript · clinical analysis · interpretation of results · draft manuscript preparation
schoolUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Claudia Ramirez-Renteria
reviewed the results · approved the final version of the manuscript · clinical analysis · interpretation of results · draft manuscript preparation
schoolUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
person Ernesto Sosa-Eroza
reviewed the results · approved the final version of the manuscript · clinical analysis · interpretation of results · clinical analysis · interpretation of results
schoolServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
reviewed the results · approved the final version of the manuscript · case conception · design · draft manuscript preparation
schoolServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
SCIMAGO INSTITUTIONS RANKINGS
Servicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoServicio de Endocrinología, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
Unidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, MéxicoUMAE Hospital de EspecialidadesMéxicoCiudad de México, MéxicoUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
Figures | Tables
imageFigure 1 (A) Frontal, lateral and posterior view of the patient. Abnormal fat distribution is evident with accumulation of fat in the neck, face, dorsocervical region, and labia majora. Also, a lack of fat in the lower limbs; significant hypertrophy of thighs and calves. (B, C) Increased accumulation of subcutaneous adipose tissue in the face, neck, superior chest and back. Hepatomegaly. (D) Decreased accumulation of subcutaneous adipose tissue in the lower limbs. open_in_new

imageFigure 2 Pathogenic variant in the LMNA gene (rs57830985 c. G1745A, p. R582H) open_in_new

table_chartTable 1
Biochemical evaluation
| Parameter | Patient values | Reference values |
|---|---|---|
| UFC μg/24 h (nmol/d) | 49.5 (136.6) | 4.3-176 (11.8-485) |
| LDDST cortisol μg /dL (nnom/L) | 0.19 (5.24) | <1.8 (<49.68) |
| Fasting glucose mg/dL (mmol/L) | 212 (11.76) | 70-100 (3.9-5.5) |
| Hb1Ac % (mmol/mol) | 9.1 (45) | 4.0%-5.6% (20-38) |
| HOMA-IR | 23 | <2.5 |
| Triglycerides mg/dL (mmol/L) | 1,004 (11.37) | <150 (<1.70) |
| Total cholesterol mg/dL (mmol/L) | 262 (6.78) | <200 (<5.18) |
| HDL-C mg/dL (mmol/L) | 37 (0.95) | >50 (1.29) |
| Total bilirubin mg/dL (mmol/L) | 0.37 (6.29) | 0.3-1.20 (5.1-20.5) |
| AST μ/L (mkat/L) | 23 (0.37) | 20-48 (0.33-0.80) |
| ALT μ/L (mkat/L) | 34 (0.578) | 10-40 (0.17-0.67) |
| GGT μ/L (mkat/L) | 52 (0.78) | 9-56 (0.135-0.84) |
| Alkaline phosphatase U/L (μkat/L) | 108 (1.8) | 40-150 (0.67-2.5) |
| FSH mUI/mL (IU/L) | 5.01 (5.0) | 2.5-12.5 (2.0-12) |
| LH mUI/mL (IU/L) | 7.81 (7.0) | 2.4-12.6 (2-18) |
| Estradiol pg/mL (pmol/L) | 34.12 (122) | 19.0-144.0 (68.4-518) |
| Prolactin ng/mL (nmol/L) | 9.39 (0.33) | 4.79-23.3 (0.17-1.00) |
| Total testosterone ng/dL (nmol/L) | 32.7 (1.2) | 2.0-45 (0.075-1.68) |
| Androstenedione ng/mL (nmol/L) | 1.99 (6.9) | 0.3-3.5 (1.04-12.2) |
| DHEA-S ug/dL (mmol/L) | 244.4 (6.6) | 45-270 (1.21-7.3) |
| ACTH Stimulation Test 17α-OH progesterone basal ng/mL (nmol/L) 17α-OH progesterone 60 min ng/mL (nmol/L) |
0.9 (2.72) 3.47 (10.5) |
<2.0 (6.05) < 5.0 (15.13) |
table_chartTable 2
Whole-exome sequencing Results
| Gene | Variant | ACMG Classification | Clinical associations |
|---|---|---|---|
| LMNA | Type: SNV Genomic position:1:156138534(GRCh38) cDNA: c.1745G>A Protein: p.Arg582His Zygosity: Heterozygous rs57830985 |
Conflicting classifications of pathogenicity Pathogenic (2); Likely pathogenic (1); Uncertain significance (2) |
Familial partial lipodystrophy type 2 |
| VDR | Type: SNV Genomic position: 12:47879112 (GRCh38) cDNA: c.2T>C Protein: p.Met1Thr Zygosity: Heterozygous rs2228570 |
Benign | Inconsistent association with obesity traits. Type 2 diabetes |
| PIK3R1 | Type: SNV Genomic position: 5:68292320 (GRCh38) cDNA: c.978G>A Protein: p.Met326Ile Zygosity: Heterozygous rs3730089 |
Benign/Likely benign | Increased risk of Type 2 diabetes, obesity and dyslipidemia |
| GCKR | Type: SNV Genomic position: 2:27508073 (GRCh38) cDNA: c.1337T>C Protein: p.Leu446Pro Zygosity: Heterozygous rs1260326 |
Benign | Severe hypertriglyceridemia, non-alcoholic steatohepatitis |
| LHCGR | Type: SNV Genomic position: 2:48694236 (GRCh38) cDNA: c.935A > G Protein: p. Asn312Ser Zygosity: Heterozygous rs2293275 |
Benign | Acne, hirsutism, high levels of LH and a greater degree of hyperandrogenism, PCOS. |
| AKR1C3 | Type: SNV Genomic position: 10:5094459 (GRCh38) cDNA: c.15C>G Protein: p.His5Gln Zygosity: Heterozygous rs12529 |
Benign | Increased levels of testosterone. Association of insulin resistance with hyperandrogenism. |
| CYP21A2 | Type: SNV Genomic position: 6:32040110 (GRCh38) cDNA: c.844G>T Protein: p.Val282Leu Zygosity: Heterozygous rs6471 |
Pathogenic/Likely pathogenic | Nonclassic congenital adrenal hyperplasia |
table_chartTable 3
Comparison of clinical and biochemical characteristics in typical FPLD2, atypical FPLD2 and our patient
| Clinical characteristic | Typical FPLD2 | Atypical FPLD2 | Our patient |
|---|---|---|---|
| Symptoms onset | After puberty | After puberty | After puberty |
| Age of diagnosis | 43 years | 42 years | 32 years |
| BMI (kg/m2) | 24.1 | 25.4 | 34 |
| Glucose (mg/dL) | 100 | 88 | 212 |
| Insulin (µIU/mL) | 10.5 | 6.9 | 44.26 |
| Hb1Ac% | 5.6 | 5.3 | 9.1 |
| Cholesterol (mg/dL) | 216 | 222 | 262 |
| HDL-C (mg/dL) | 32 | 42 | 37 |
| Triglycerides (mg/dL) | 573 | 192 | 1004 |
| Fat distribution | Fat accumulation in face, neck, armpits, interscapular area, labia majora and visceral. Fat loss in the limbs, buttocks, trunk. | Fat accumulation in face, neck, armpits, interscapular area, labia majora and visceral. Less fat loss in the limbs and buttocks. | Fat accumulation in face, neck, armpits, interscapular area, labia majora and visceral. Fat loss in the limbs and buttocks. |
| Hirsutism | + | - | + |
| Acanthosis nigricans | + | - | + |
| Oligomenorrhea | + | - | + |
| Calf hypertrophy | ++ | + | + |
| Myalgias/muscular weakness | + | - | + |
| Subcutaneous lipoma | + | - | ++ |
| Hepatic steatosis | + | - | + |
How to cite
location_on
Sociedade Brasileira de Endocrinologia e Metabologia
Rua Botucatu, 572 - Conjuntos 81/83, CEP: 04023-061 , Tel: +55 (11) 5575-0311 / +55 (11) 9 9768-6933 -
São Paulo -
SP -
Brazil
E-mail: aem.editorial.office@endocrino.org.br
E-mail: aem.editorial.office@endocrino.org.br
rss_feed
Acompañe los números de esta revista en su lector de RSS
Versão para download de PDF
Artículos relacionados
Lista de links para artigos relacionados. Os links abrem em nova aba.
Versões e tradução automática
Escolha a versão original do texto ou utilize um serviço de tradução automática.
Versão original do texto
Como citar
Escolha um formato para exportar ou selecione um estilo de citação. O conteúdo abaixo pode ser atualizado após a seleção.
Thumbnail
Thumbnail